SEC Form 4 · accession 0001209191-17-006265
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abhay Joshi
Officer — Chief Operating Officer
Period of report
Jan 26, 2017
Accepted (ET)
Jan 30, 2017 · 9:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 26, 2017 | A | 13,100 | $0.00 | A | 80,912 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $19.70 | Jan 26, 2017 | A | 79,000 | A | — | Jan 25, 2027 | Common Stock | 79,000 | 79,000 | D |
Explanation of responses
- F1The shares subject to the Restricted Stock Award shall vest in three (3) equal annual installments beginning from February 15, 2017, subject to Dr. Joshi's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date.
- F2The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 26, 2017, subject to Dr. Joshi's Continuous Service (as defined in the Plan) on each vesting date.